New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
05:33 EDTMKGAYMerck KGaA downgraded to Neutral from Buy at Nomura
News For MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
08:12 EDTMKGAYIntrexon, Merck Serono announce agreement for CAR-T development
Subscribe for More Information
08:12 EDTMKGAYZiopharm-Intrexon announce collaboration with Merck KGaA for CAR-T products
ZIOPHARM Oncology (ZIOP) and Intrexon (XON) announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell, or CAR-T, products with Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY). Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration with Intrexon.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use